Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Peptides and Muscle Building Marek Wawrzyk

MK-677 growth hormone tablets

Let us begin with a clarification that lies at the heart of the topic: MK-677 is not growth hormone in tablet form.

MK-677 growth hormone tablets

Let us begin with a clarification that lies at the heart of the topic: MK-677 is not growth hormone in tablet form. It does not contain somatotropin or deliver it to the body. It is a molecule that acts on the mechanism responsible for secreting endogenous growth hormone. This mechanistic distinction has real consequences, including for the risk profile. The popular name has become common shorthand and remains in the title because it reflects how people search for the topic, but the article describes the compound for what it actually is.

All substances discussed in this article are research compounds and are not intended for human consumption. The description of their activity is based solely on laboratory findings and experimental observations, not on clinical use.

What is growth hormone and why is it so important?

Growth hormone (GH, somatotropin) is a protein secreted in a pulsatile manner by the pituitary gland. During growth, it is responsible for the development of bones and tissues; in adults, it participates in the regulation of body composition, protein and lipid metabolism, and repair processes. Much of its action is indirect – through insulin-like growth factor 1 (IGF-1), the production of which is induced by GH primarily in the liver.

This duality is important for understanding the rest: the GH/IGF-1 axis is not a “more muscle” switch, but a regulatory system with many points of control – also including carbohydrate metabolism and water and electrolyte metabolism.

MK-677 is not a SARM and not a growth hormone – what it really is

MK-677 (ibutamoren) is a non-peptide, orally active growth hormone secretagogue – ghrelin receptor (GHS-R) agonist. It imitates the action of ghrelin, a hormone secreted mainly in the stomach, which, in addition to regulating appetite, stimulates the secretion of GH by the pituitary gland. The role of this receptor has been described in a review (Laviano et al., 2012, PMID 22632856), and its distribution in the central nervous system has been characterized separately (Airapetov et al., 2021, PMID 34755494).

Two distinctions that are often confused in practice:

MK-677 is NOT Why
SARM does not bind the androgen receptor; SARMs belong to WADA category S1.2, whereas MK-677 belongs to S2. The classification of the entire group is discussed in the article on SARMs for bodybuilders
growth hormone does not supply exogenous somatotropin, but stimulates endogenous secretion – a mechanism that depends on pituitary function and preserves physiological pulsatility

How MK-677 works – mechanism

Activation of the GHS-R receptor in the pituitary and hypothalamus increases the secretion of growth hormone, which translates into an increase in IGF-1 concentration. Because the compound is non-peptide, it is not subject to proteolytic digestion in the gastrointestinal tract – hence its activity after oral administration, distinguishing it from peptide secretagogues.

The same receptor is responsible for the second, well-documented effect: increased appetite. This is not an “incidental” side effect, but a direct consequence of the ghrelin mechanism – ghrelin is a hormone that signals hunger.

What do human studies show

Clinical data do exist for MK-677, and they are worth presenting carefully because the findings are more nuanced than the popular narrative suggests.

Nitrogen balance under caloric restriction

In a 1998 double-blind, placebo-controlled crossover study involving eight healthy volunteers undergoing caloric restriction, MK-677 reversed the negative nitrogen balance induced by the diet (Murphy et al., 1998, PMID 9467534). This was a small, short-term study focused on a specific biochemical parameter, not on muscle gain in people who train.

One-year randomized trial in older people

The most important data come from a one-year study in healthy older adults. MK-677 increased growth hormone and IGF-1 concentrations to levels observed in young adults, and fat-free mass increased by 1.1 kg compared with a decrease of 0.5 kg in the placebo group. At the same time, the study found:

  • an increase in fat-free mass without an improvement in strength or functional performance,
  • increase in fasting glucose concentration by an average of 0.3 mmol/l and decrease in insulin sensitivity,
  • increase in cortisol concentration,
  • greater increase in fat tissue in the limbs than in the placebo group,
  • transient swelling of the lower limbs and muscle pain as the most common side effects (Nass et al., 2008, PMID 18981485).

The first point deserves emphasis because it is rarely quoted: an increase in measured fat-free mass did not translate into greater strength. The authors also noted that the study lacked sufficient statistical power to assess functional endpoints fully.

Evidence of desensitization from an animal model

The following observations are from a study on rats. There are no human studies confirming these observations in this regard.

A study published in 2018 assessed the effect of prolonged oral administration of MK-677 on growth in rats. The result was the opposite of what might have been expected: six weeks of administration did not promote growth and abolished the stimulatory effect of MK-677 on growth hormone secretion. The authors associated this phenomenon with increased somatostatin expression in the hypothalamus, meaning activation of a physiological brake on the axis (Lee et al., 2018, PMID 30450851).

This observation matters because it challenges the assumption that longer exposure produces proportionally greater effects. A rodent model cannot be translated directly to humans, but it cannot simply be ignored when it concerns the same molecule and the same route of administration. Studies of other secretagogues have produced a different picture: short-term administration of hexarelin in older adults did not desensitize the GH response (Ghigo et al., 1996, PMID 8921821). The question remains open and may depend on the specific compound and duration of exposure.

Harm reduction – insulin resistance, fluid retention, IGF-1 axis

Glucose metabolism

This is the best documented element of the risk profile. In a 1-year randomized trial, fasting glucose levels increased and insulin sensitivity decreased (PMID 18981485). The mechanism is consistent with physiology: growth hormone has an opposite effect to insulin (counterregulatory), so increasing its concentration affects the carbohydrate metabolism in a predictable direction.

This is not an inconvenience that can be “corrected” by adding another research compound. Attempting to counteract one effect with a second compound does not remove the problem; it adds another variable with its own independent risk profile. This applies in particular to GW-501516, whose clinical development was halted after tumors emerged in long-term animal toxicology studies and which prompted a WADA public health warning in 2013. A case of poisoning following simultaneous exposure to GW1516 and ostarine has also been described (Kintz et al., 2021, PMID 34678947). Presenting this combination as a solution to a glycemic problem was an error that we removed from the previous version of this article.

Fluid retention

Lower limb swelling and muscle pain were the most frequently reported side effects in the 1-year study and were transient (PMID 18981485). Numbness in the limbs is sometimes described in the context of increased extracellular fluid volume. A review of the safety of growth hormone secretagogues brings together these observations along with the limitations of available data (Sigalos and Pastuszak, 2018, PMID 28400207).

Elevated IGF-1 and the oncological context

This topic requires precision because it is easy to overinterpret in either direction. MK-677 increases IGF-1 concentration; that is its intended pharmacological effect. Separately, epidemiological studies have observed associations between higher circulating IGF-1 concentrations and the risk of certain cancers: breast cancer (Hankinson et al., 1998, PMID 9593409), colorectal cancer in the EPIC cohort and a meta-analysis of prospective studies (Rinaldi et al., 2010, PMID 19810099), and prostate cancer in an analysis of 200,000 men from UK Biobank (Watts et al., 2021, PMID 33252839).

What can and cannot be concluded from this? It does not show that MK-677 causes cancer; no studies have assessed long-term oncological endpoints for this compound, so those data simply do not exist. It does show, however, that prolonged pharmacological elevation of IGF-1 affects an axis whose association with cancer risk is being studied epidemiologically, while no one has measured that risk for MK-677 itself. An absence of data is not evidence that the risk is absent.

What research on the GHRH and GHRP axis shows

The somatotropin axis has two distinct pharmacological control points, which has been the subject of research since the 1990s.

The literature describes responses with different characteristics at these two pharmacological targets, which explains researchers’ interest in comparing them within experimental systems. This is an observation about study design, not a recommendation to combine products: every additional compound introduces another variable, including another source of risk, and no human safety profile has been established for any such combination. Compounds studied within this axis are reviewed in the article on peptides and SARMs for muscle building.

Natural factors influencing the secretion of growth hormone

Physiological GH secretion is regulated by factors that do not require any pharmacology:

  • Sleep – the largest secretory pulses occur in the deep sleep phase, which makes the quality and length of sleep the basic factor regulating this axis.
  • Physical activity – exercise, especially high intensity, is associated with an increase in GH secretion.
  • Meal composition and distribution – protein supply and glycemic status influence the secretory profile of the axis.
  • Chronic stress – persistent elevation of cortisol affects the regulation of the somatotropin axis.

This is worth noting not as consolation, but as a physiological fact: these factors act on the same system that researchers may seek to modulate pharmacologically, without carrying the risk profile described in the previous sections.

Regulatory status and anti-doping notice

MK-677 is not registered as a medicinal product in any jurisdiction. It is not a dietary supplement or food and is not eligible for health claims. It remains a research-grade compound.

WADA status: category S2 – peptide hormones, growth factors, related substances and mimetics. MK-677 is listed as a growth hormone secretagogue and is prohibited at all times, both in and out of competition. This differs from category S1.2 assigned to SARMs, directly reflecting the compounds’ different mechanisms.

Anti-doping regulations are not limited to professionals. In Poland, the WADA Prohibited List is implemented through the Polish Anti-Doping Agency (POLADA), and amateur athletes competing in events covered by these rules may also be tested. Because MK-677 is not a registered drug, there is no route to obtain a therapeutic use exemption (TUE). Its current status should always be checked against the applicable version of the Prohibited List.

A separate practical point: in an analysis of products sold online as SARMs, ibutamoren was among the substances detected as undeclared ingredients (Van Wagoner et al., 2017, PMID 29183075). For an athlete subject to testing, this creates a risk of an anti-doping violation involving a substance they did not knowingly select.

Frequently asked questions

Is MK-677 growth hormone in tablet form?

No. MK-677 does not contain somatotropin. It is a secretagogue, meaning a compound that stimulates the pituitary gland to release endogenous growth hormone by acting through the ghrelin receptor. The common name is shorthand.

Is MK-677 a SARM?

No. It does not bind the androgen receptor. On the WADA Prohibited List, it is included in category S2 (peptide hormones and mimetics), not category S1.2 assigned to SARMs.

Does MK-677 increase strength?

In a 1-year randomized trial in healthy older adults, fat-free mass increased but no changes in strength or functional ability were observed (PMID 18981485). The authors noted the limited power of the study to assess functional endpoints.

Does MK-677 affect blood glucose?

Yes. In the one-year study, fasting glucose increased and insulin sensitivity decreased. This is consistent with growth hormone’s counter-regulatory effect on insulin and is a documented part of the compound’s profile.

Is elevated IGF-1 associated with cancer risk?

Epidemiological studies have observed associations between higher circulating IGF-1 concentrations and the risk of certain cancers (PMID 9593409, 19810099, 33252839). However, no studies have assessed long-term oncological endpoints for MK-677 itself. The absence of such data is not evidence that the risk is absent.

Why does the article not provide doses or cycle lengths?

Because MK-677 is not an approved medicinal product and has not undergone a registration process in which dosing is established. In addition, an animal study indicates that prolonged exposure may abolish the compound’s stimulatory effect on GH secretion (PMID 30450851), calling into question the premise that longer cycles necessarily produce greater effects.

Summary

MK-677 (ibutamoren) is a non-peptide, orally active growth hormone secretagogue and ghrelin-receptor agonist. It is neither growth hormone nor a SARM. It appears in category S2 of the WADA Prohibited List and is prohibited at all times, including for amateur athletes covered by POLADA rules. Clinical evidence includes a study of nitrogen balance under caloric restriction and a one-year randomized study in healthy older adults. The latter showed increases in GH, IGF-1, and fat-free mass, but no improvement in strength or functional performance, alongside higher fasting glucose, reduced insulin sensitivity, and increased cortisol. In an animal model, prolonged administration abolished the compound’s stimulatory effect on GH secretion, challenging assumptions about benefits from long-term exposure. Its impact on glucose metabolism is a documented part of the profile, not a problem to be corrected by adding another research compound. Pharmacological elevation of IGF-1 affects an axis whose association with cancer risk has been studied epidemiologically, while long-term data for MK-677 itself are absent.

Product documentation

Research material cards along with batch analytical documentation are available in the categories peptides and SARMs and modulators. Materials intended for research use only.

Bibliography

  1. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485
  2. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320-325. PMID: 9467534
  3. Lee J, Kwon A, Chae HW, Lee WJ, Kim TH, Kim HS. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei Med J. 2018;59(10):1174-1180. PMID: 30450851
  4. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207
  5. Laviano A, Molfino A, Rianda S, Rossi Fanelli F. The growth hormone secretagogue receptor (Ghs-R). Curr Pharm Des. 2012;18(31):4749-4754. PMID: 22632856
  6. Airapetov MI, Eresko SO, Lebedev AA, Bychkov ER, Shabanov PD. Expression of the growth hormone secretagogue receptor 1a (GHS-R1a) in the brain. Physiol Rep. 2021;9(21):e15113. PMID: 34755494
  7. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analogue of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
  8. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445-460. PMID: 9186261
  9. Ghigo E, Arvat E, Gianotti L, et al. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol. 1996;135(4):407-412. PMID: 8921821
  10. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351(9113):1393-1396. PMID: 9593409
  11. Rinaldi S, Cleveland R, Norat T, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer. 2010;126(7):1702-1715. PMID: 19810099
  12. Watts EL, Fensom GK, Smith Byrne K, et al. Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200,000 men in the UK Biobank. Int J Cancer. 2021;148(9):2274-2288. PMID: 33252839
  13. Kintz P, Gheddar L, Paradis C, et al. Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR-delta) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine). Toxics. 2021;9(10):251. PMID: 34678947
  14. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017;318(20):2004-2010. PMID: 29183075